Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Healhty, Chronic Spontaneous Urticaria (CSU)
- Main trialPhase 1/2
- “NN2802 is a new product that is being developed for treating participants with CSU who remain symptomatic despite treatment with antihistamines. NN2802 is not yet an approved product and it can only be used in an experimental study like this one. The purpose of this study is to learn more about a new experimental drug called NN2802. NN2802 is an investigational fully human monoclonal antibody that inhibits c-Kit. c-Kit is involved in the survival, development, and activity of mast cells, which are important cells involved in allergic and inflammatory reactions. By inhibiting c-Kit, NN2802…”In the company’s words, NCT07930572 on ClinicalTrials.gov
Other drugs for Healhty
- RemibrutinibNovartis · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- JYB1904Jemincare · Phase 3
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- LP-003Longbio Pharma · Phase 3
- BarzolvolimabCelldex Therapeutics · Phase 3
Coming up1
- 31 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovNew trial: none to Phase 1/2 · ClinicalTrials.gov NCT07930572
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Mar 2027 | A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026